Hikal Ltd Q3 FY25 Earnings Analysis

Published 26 May 2026 | Market Cap: ₹2.9K Cr

Price

₹218

Market Cap

₹2.9K Cr

P/E Ratio

79.0

Earnings Summary

Hikal anticipates high teens year-on-year CAGR growth over the next 3 to 5 years, targeting mid- to high teens annual growth. Hikal anticipates mid- to high-teens CAGR growth over the next 3 to 5 years, targeting FY'28 as a reference point for progress.

📊 Revenue & Sales Performance

→Hikal anticipates high teens year-on-year CAGR growth over the next 3 to 5 years, targeting mid- to high teens annual growth.
→By FY '28, revenue to grow significantly from FY '24 levels, supported by new product launches in Pharma and Agrochem sectors.
→Pharma business growth driven by 13-14 CDMO products in pipeline, two near commercialization by FY '26 end; majority launching FY '27 onwards.
→Crop protection division sees stabilization with increasing domestic demand and innovative CDMO projects; 8 active CDMO products in pipeline.
→Veterinary segment expected to grow to INR400+ crores over the next 5 years, becoming a standalone division.
→Project Pinnacle strategy to enhance market positioning, operational efficiency, and support sustained revenue and margin growth.
→Overall focus on specialty chemicals, NCEs, and CDMO to boost volumes and value growth.
→Crop protection 9M volume growth: 41%, value degrowth: -3.3%; Pharma volume growth: 3.7%, value growth: 7.1%.

📈 Profitability & Margins

→Hikal anticipates mid- to high-teens CAGR growth over the next 3 to 5 years, targeting FY'28 as a reference point for progress.
→EBITDA margins are expected to surpass 20%, aiming well beyond that threshold, driven by operational leverage and focus on CDMO pipeline involving proprietary products and NCEs.
→Pharma business EBIT margin showed improvement YoY, though quarterly fluctuations occur due to product mix and shipment phasing.
→Crop Protection division is stabilizing with innovation and restructuring towards specialty chemicals and NCEs, supporting medium to long-term growth.
→Animal Health business projected to grow over INR400 crores in 5 years, establishing itself as a standalone segment.
→Project Pinnacle strategy aligns for sustainable margin expansion and revenue growth.
→Overall, revenue growth of 15%-20% per annum is targeted, with plans for INR150-200 crores capex annually to support expansion and debottlenecking.

🏗️ Capital Expenditure Plans

→Current year capex is guided at INR140 crores to INR150 crores, as per earlier guidance.
→For FY '26, planned capex is around INR150 crores to INR200 crores annually.
→Of this, 30% to 40% will be replacement and maintenance capex, with the balance allocated to debottlenecking and growth capex.
→The Agrochem plant capitalization amounted to INR340 crores last month.
→The company is continuously investing about 4.5% to 5% of revenue into R&D to drive innovation and meet customer demands.
→Strategic investments include focusing on new CDMO projects, NCEs, and specialty chemicals, leveraging existing infrastructure for higher-margin products.
→Project Pinnacle is a transformational initiative aimed at positioning the company for future growth through strategic realignment, operational efficiency, and market expansion.

💰 Fundraising & Capital Structure

→No explicit mention of any new fundraising through debt or equity in the provided transcript.
→Current gross debt as of December 2024 is INR 731 crores.
→The company is generating positive operating cash flow of INR 102 crores for 9 months.
→Capex plans continue as guided (INR 140–150 crores for current year, INR 150–200 crores for FY '26).
→Focus appears to be on maintaining cash flow and capex within existing financial parameters.
→No indication of plans to raise additional capital via equity or debt during the discussed period.

📋 Order Book & Pipeline

→No explicit details on the current or expected order book or pending orders were provided in the transcript.
→The company mentioned having a strong pipeline with:
→ - About 13 to 14 Pharma CDMO products in Phase II and III trials.
→ - Several projects in Crop Protection CDMO with a strong pipeline of eight products.
→Positive traction and an increase in RFP inflows from innovator customers across Pharma, Animal Health, and Crop Protection segments were reported.
→Validation of Animal Health portfolio is in progress with several new client engagements.
→The company expects commercialization of Pharma products from FY '26 and FY '27 onwards.
→Overall, Hikal has significant ongoing projects in various stages of development and validation indicating a healthy upcoming order intake, but exact order book values are not specified.

Key Metrics

Frequently Asked Questions

What were Hikal Ltd Q3 FY25 results?

What is Hikal Ltd share price analysis?

Hikal Ltd currently shows a neutral. The stock trades at a P/E of 79.0 with a market cap of ₹2,868 Cr. Investors should review the full earnings analysis for detailed insights.

Is Hikal Ltd planning capital expenditure?

Current year capex is guided at INR140 crores to INR150 crores, as per earlier guidance.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.